Post-Marketing Surveillance Study of OTEZLA

Amgen1,086 enrolled

Overview

To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1. Planned registration period 2 years 2. Planned surveillance period for 4 years from 6 months after launch

Study Type

OBSERVATIONAL

Enrollment

1,086

Conditions

Psoriasis

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: \- Patients who have received a diagnosis of either of the following diseases and have received OTEZLA for the first time will be included in this survey. * Psoriasis vulgaris that is with an inadequate response to topical therapies * Psoriasis arthropathica Exclusion Criteria: * N/A

Locations (1)

Tugi dermatology clinic

Kitakyushu, Fukuoka, Japan

Outcomes

Primary Outcomes

Adverse Events (AEs)

Number of participants with adverse events

Time frame: Up to approximately 12 months

General Improvement Rating

General Improvement Rating will be assessed by physician's observation